Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease

Ming-Feng Dong, Zeng-Shan Ma, Lexin Wang, Sheng-Jun Ma, Shou-Dong Chai, Pei-Zhe Tang, Dao-Kuo Yaim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To evaluate the therapeutic effects of prostaglandin E1 (PGE1) on residual pulmonary arterial hypertension (PAH) after corrective surgery for congenital heart disease. Methods: Thirty-one patients with postoperational PAH were randomly divided into control group (n = 15) and PGE1 group (n = 16, 6 courses of intravenous PGE1 plus conventional therapy). Mean pulmonary arterial pressure (MPAP), right ventricular ejection fraction (RVEF), and left ventricular ejection fraction (LVEF) were measured by echocardiography before and 3, 6, and 12 months after the treatment. Arterial oxygen pressure (Pao 2) was monitored. Results: In both groups, MPAP decreased and RVEF, LVEF, and Pao 2 increased at 6 and 12 months following surgery. In the PGE1 group, the MPAP (32.2 ± 5.2 vs 40.2 ± 5.1 mm Hg; P = .008) was lower and RVEF (66.6% ± 6.5% vs 54.9% ± 2.1%; P = .019), LVEF (65.9% ± 3.9% vs 53.5% ± 5.1%; P = .031), and Pao 2 (94.3% ± 11.2% vs 93.1% ± 11.3%; P = .009) was higher than in the control group 12 months after the surgery. Four patients (26.7%) in the control group died of pulmonary hypertension crisis, but there was no death in the PGE1 group (P = .029). Cumulative survival rate in the control group were 86.7%, 80%, 73.3%, and 73.3% at 1, 2, 3, and 5 years, respectively. Conclusions: Intravenous PGE1 therapy after corrective surgery for congenital heart disease was associated with a reduction in mean pulmonary arterial pressure and a lower risk of death.
Original languageEnglish
Pages (from-to)303-307
Number of pages5
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume17
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Alprostadil
Pulmonary Hypertension
Stroke Volume
Heart Diseases
Arterial Pressure
Lung
Control Groups
Therapeutic Uses
Echocardiography
Therapeutics
Survival Rate
Oxygen

Cite this

Dong, Ming-Feng ; Ma, Zeng-Shan ; Wang, Lexin ; Ma, Sheng-Jun ; Chai, Shou-Dong ; Tang, Pei-Zhe ; Yaim, Dao-Kuo. / Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2012 ; Vol. 17, No. 3. pp. 303-307.
@article{e5632727111f48eaab2014489a50e4bf,
title = "Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease",
abstract = "Objective: To evaluate the therapeutic effects of prostaglandin E1 (PGE1) on residual pulmonary arterial hypertension (PAH) after corrective surgery for congenital heart disease. Methods: Thirty-one patients with postoperational PAH were randomly divided into control group (n = 15) and PGE1 group (n = 16, 6 courses of intravenous PGE1 plus conventional therapy). Mean pulmonary arterial pressure (MPAP), right ventricular ejection fraction (RVEF), and left ventricular ejection fraction (LVEF) were measured by echocardiography before and 3, 6, and 12 months after the treatment. Arterial oxygen pressure (Pao 2) was monitored. Results: In both groups, MPAP decreased and RVEF, LVEF, and Pao 2 increased at 6 and 12 months following surgery. In the PGE1 group, the MPAP (32.2 ± 5.2 vs 40.2 ± 5.1 mm Hg; P = .008) was lower and RVEF (66.6{\%} ± 6.5{\%} vs 54.9{\%} ± 2.1{\%}; P = .019), LVEF (65.9{\%} ± 3.9{\%} vs 53.5{\%} ± 5.1{\%}; P = .031), and Pao 2 (94.3{\%} ± 11.2{\%} vs 93.1{\%} ± 11.3{\%}; P = .009) was higher than in the control group 12 months after the surgery. Four patients (26.7{\%}) in the control group died of pulmonary hypertension crisis, but there was no death in the PGE1 group (P = .029). Cumulative survival rate in the control group were 86.7{\%}, 80{\%}, 73.3{\%}, and 73.3{\%} at 1, 2, 3, and 5 years, respectively. Conclusions: Intravenous PGE1 therapy after corrective surgery for congenital heart disease was associated with a reduction in mean pulmonary arterial pressure and a lower risk of death.",
keywords = "Congenital heart disease, Prostaglandin E1, Residual pulmonary hypertension, Ventricular function mortality",
author = "Ming-Feng Dong and Zeng-Shan Ma and Lexin Wang and Sheng-Jun Ma and Shou-Dong Chai and Pei-Zhe Tang and Dao-Kuo Yaim",
note = "Imported on 12 Apr 2017 - DigiTool details were: month (773h) = September, 2012; Journal title (773t) = Journal of Cardiovascular Pharmacology and Therapeutics. ISSNs: 1074-2484;",
year = "2012",
month = "9",
doi = "10.1177/1074248411429966",
language = "English",
volume = "17",
pages = "303--307",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "3",

}

Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease. / Dong, Ming-Feng; Ma, Zeng-Shan; Wang, Lexin; Ma, Sheng-Jun; Chai, Shou-Dong; Tang, Pei-Zhe; Yaim, Dao-Kuo.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 17, No. 3, 09.2012, p. 303-307.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease

AU - Dong, Ming-Feng

AU - Ma, Zeng-Shan

AU - Wang, Lexin

AU - Ma, Sheng-Jun

AU - Chai, Shou-Dong

AU - Tang, Pei-Zhe

AU - Yaim, Dao-Kuo

N1 - Imported on 12 Apr 2017 - DigiTool details were: month (773h) = September, 2012; Journal title (773t) = Journal of Cardiovascular Pharmacology and Therapeutics. ISSNs: 1074-2484;

PY - 2012/9

Y1 - 2012/9

N2 - Objective: To evaluate the therapeutic effects of prostaglandin E1 (PGE1) on residual pulmonary arterial hypertension (PAH) after corrective surgery for congenital heart disease. Methods: Thirty-one patients with postoperational PAH were randomly divided into control group (n = 15) and PGE1 group (n = 16, 6 courses of intravenous PGE1 plus conventional therapy). Mean pulmonary arterial pressure (MPAP), right ventricular ejection fraction (RVEF), and left ventricular ejection fraction (LVEF) were measured by echocardiography before and 3, 6, and 12 months after the treatment. Arterial oxygen pressure (Pao 2) was monitored. Results: In both groups, MPAP decreased and RVEF, LVEF, and Pao 2 increased at 6 and 12 months following surgery. In the PGE1 group, the MPAP (32.2 ± 5.2 vs 40.2 ± 5.1 mm Hg; P = .008) was lower and RVEF (66.6% ± 6.5% vs 54.9% ± 2.1%; P = .019), LVEF (65.9% ± 3.9% vs 53.5% ± 5.1%; P = .031), and Pao 2 (94.3% ± 11.2% vs 93.1% ± 11.3%; P = .009) was higher than in the control group 12 months after the surgery. Four patients (26.7%) in the control group died of pulmonary hypertension crisis, but there was no death in the PGE1 group (P = .029). Cumulative survival rate in the control group were 86.7%, 80%, 73.3%, and 73.3% at 1, 2, 3, and 5 years, respectively. Conclusions: Intravenous PGE1 therapy after corrective surgery for congenital heart disease was associated with a reduction in mean pulmonary arterial pressure and a lower risk of death.

AB - Objective: To evaluate the therapeutic effects of prostaglandin E1 (PGE1) on residual pulmonary arterial hypertension (PAH) after corrective surgery for congenital heart disease. Methods: Thirty-one patients with postoperational PAH were randomly divided into control group (n = 15) and PGE1 group (n = 16, 6 courses of intravenous PGE1 plus conventional therapy). Mean pulmonary arterial pressure (MPAP), right ventricular ejection fraction (RVEF), and left ventricular ejection fraction (LVEF) were measured by echocardiography before and 3, 6, and 12 months after the treatment. Arterial oxygen pressure (Pao 2) was monitored. Results: In both groups, MPAP decreased and RVEF, LVEF, and Pao 2 increased at 6 and 12 months following surgery. In the PGE1 group, the MPAP (32.2 ± 5.2 vs 40.2 ± 5.1 mm Hg; P = .008) was lower and RVEF (66.6% ± 6.5% vs 54.9% ± 2.1%; P = .019), LVEF (65.9% ± 3.9% vs 53.5% ± 5.1%; P = .031), and Pao 2 (94.3% ± 11.2% vs 93.1% ± 11.3%; P = .009) was higher than in the control group 12 months after the surgery. Four patients (26.7%) in the control group died of pulmonary hypertension crisis, but there was no death in the PGE1 group (P = .029). Cumulative survival rate in the control group were 86.7%, 80%, 73.3%, and 73.3% at 1, 2, 3, and 5 years, respectively. Conclusions: Intravenous PGE1 therapy after corrective surgery for congenital heart disease was associated with a reduction in mean pulmonary arterial pressure and a lower risk of death.

KW - Congenital heart disease

KW - Prostaglandin E1

KW - Residual pulmonary hypertension

KW - Ventricular function mortality

U2 - 10.1177/1074248411429966

DO - 10.1177/1074248411429966

M3 - Article

VL - 17

SP - 303

EP - 307

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 3

ER -